Short Bowel Syndrome Drug Pipeline Analysis Report 2025

Short bowel syndrome is a rare condition characterized by insufficient small bowel length, typically less than 180-200 cm in adults. The disease affects approximately 1-2 per 100,000 individuals annually. Current treatment options, such as parenteral nutrition, fail to fully address the clinical needs of patients with short bowel syndrome, creating a significant unmet need for more effective therapies. With ongoing advancements in biologics, regenerative medicine, and surgical interventions, there is growing hope for improved treatment options. Additionally, the increasing focus on personalized medicine and precision therapies is expected to drive pipeline growth in the coming years, offering potential breakthroughs for managing short bowel syndrome.

Report Coverage

The Short Bowel Syndrome Drug Pipeline Insight Report by the publisher provides comprehensive insights into short bowel syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for short bowel syndrome. The short bowel syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The short bowel syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with short bowel syndrome treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to short bowel syndrome.

Short Bowel Syndrome Drug Pipeline Outlook

Short bowel syndrome is a malabsorptive disorder that occurs when a significant portion of the small intestine is surgically removed or damaged, typically due to conditions such as Crohn’s disease, trauma, or cancer. This leads to inadequate nutrient absorption, resulting in malnutrition and dehydration.

Short bowel syndrome treatment focuses on managing symptoms and improving nutrient absorption. Common options include parenteral nutrition, enteral feeding, and medications such as glutamine or teduglutide. In severe cases, small bowel transplantation may be considered for patients with a poor prognosis.

Short Bowel Syndrome Epidemiology

A 2024 study on short bowel syndrome revealed the global prevalence to be approximately 1 to 2 cases per 100,000 individuals annually. In the United States, the incidence ranges from 0.3 to 4 cases per 100,000 inhabitants, while in Europe, it varies between 0.1 and 4 cases per 100,000. These findings highlight the rare but significant impact of short bowel syndrome on affected populations.

Short Bowel Syndrome Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of short bowel syndrome drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Cell Therapies
• Peptides
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Short Bowel Syndrome Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total short bowel syndrome clinical trials.

Short Bowel Syndrome - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the short bowel syndrome pipeline analysis include cell therapies, peptides, and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for short bowel syndrome.

Short Bowel Syndrome Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the short bowel syndrome report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in short bowel syndrome clinical trials:

• Chongqing Peg-Bio Biopharm Co., Ltd.
• VectivBio AG
• Hanmi Pharmaceutical Company Limited
• Zealand Pharma
• Napo Pharmaceuticals, Inc.

Short Bowel Syndrome Emerging Drugs Profile

This section covers a detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for short bowel syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of short bowel syndrome drug candidates.

Drug: Apraglutide

Sponsored by VectivBio AG, the Phase 3 study aims to evaluate the long-term safety and tolerability of apraglutide in patients with short bowel syndrome. The study, involving 158 participants, will assess the drug's safety, efficacy, and durability over up to 208 weeks. The study’s completion is anticipated by October 2027.

Drug: Amoxicillin, Levofloxacin, Ofloxacin, Sulfamethoxazole-Trimethoprim

The clinical trial, sponsored by Central Hospital, Nancy, France, aims to assess the absorption of oral antibiotics, including amoxicillin, levofloxacin, ofloxacin, and sulfamethoxazole-trimethoprim, in patients with short bowel syndrome. The Phase 1 study is expected to be completed by February 2025 and will involve 10 participants, evaluating the pharmacokinetic profiles of these antibiotics.

Reasons To Buy This Report

The Short Bowel Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for short bowel syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. Stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within short bowel syndrome pipeline insights.

Key Questions Answered in the Short Bowel Syndrome - Pipeline Insight Report

• What is the current landscape of short bowel syndrome pipeline drugs?
• Which companies/institutions are developing short bowel syndrome emerging drugs?
• How many phase II drugs are currently present in short bowel syndrome pipeline drugs?
• Which company is leading the short bowel syndrome pipeline development activities?
• What is the current short bowel syndrome therapeutic assessment?
• What are the opportunities and challenges present in the short bowel syndrome drug pipeline landscape?
• What is the efficacy and safety profile of short bowel syndrome pipeline drugs?
• Which companies/institutions are involved in short bowel syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in short bowel syndrome?

This product will be delivered within 3-5 business days.